At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Trading 05-20 15:50:09 EDT
18.43
+2.08
+12.72%
High18.85Low16.50Vol103.43K
Open16.55D1 Closing16.35Amplitude14.37%
Mkt Cap470.60MTradable Cap177.23MTotal Shares25.53M
T/O1.85MT/O Rate1.08%Tradable Shares9.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Dyne Therapeutics Is Maintained at Buy by Jefferies
Dow Jones  ·  01:42
Dyne Therapeutics Is Maintained at Buy by Jefferies
Dyne Therapeutics Shares Rise 23% on Favorable Drug Data
Dow Jones  ·  00:38
Dyne Therapeutics Shares Rise 23% on Favorable Drug Data
BUZZ- Dyne Therapeutics jumps on positive data for muscle disorder drugs
Reuters  ·  05-20 22:21
BUZZ- Dyne Therapeutics jumps on positive data for muscle disorder drugs
BRIEF-Coya Therapeutics Announces $5 Million Strategic Investment
Reuters  ·  05-20 21:27
BRIEF-Coya Therapeutics Announces $5 Million Strategic Investment
BRIEF-Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
Reuters  ·  05-20 21:23
BRIEF-Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
BRIEF-Lisata Therapeutics Receives Paediatric Investigation Plan Waiver From European Medicines Agency
Reuters  ·  05-20 21:22
BRIEF-Lisata Therapeutics Receives Paediatric Investigation Plan Waiver From European Medicines Agency
Dyne Therapeutics announces data from early stage trials of muscular dystrophy treatments
seekingalpha  ·  05-20 21:06
Dyne Therapeutics announces data from early stage trials of muscular dystrophy treatments
BRIEF-Inhibikase Therapeutics Announces Pricing Of Registered Direct Offering And Warrant Inducement, Priced At-The-Market For Aggregate Gross Proceeds Of $4.0 Million
Reuters  ·  05-20 21:01
BRIEF-Inhibikase Therapeutics Announces Pricing Of Registered Direct Offering And Warrant Inducement, Priced At-The-Market For Aggregate Gross Proceeds Of $4.0 Million
BRIEF-Allarity Therapeutics Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement
Reuters  ·  05-20 21:00
BRIEF-Allarity Therapeutics Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
PR Newswire  ·  05-20 20:30
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
Coya Therapeutics reports $5M strategic investment by ADDF
seekingalpha  ·  05-20 20:28
Coya Therapeutics reports $5M strategic investment by ADDF
Autolus Therapeutics: A Strong Buy on Promising Obe-cel Developments and Strategic Readiness
TIPRANKS  ·  05-20 20:27
Autolus Therapeutics: A Strong Buy on Promising Obe-cel Developments and Strategic Readiness
BRIEF-Ptc Therapeutics Inc Announces European Commission Returns Translarna™ Opinion To CHMP For Re-Evaluation
Reuters  ·  05-20 20:16
BRIEF-Ptc Therapeutics Inc Announces European Commission Returns Translarna™ Opinion To CHMP For Re-Evaluation
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
Business Wire  ·  05-20 20:15
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
Inhibikase Therapeutics prices its direct offering, warrant inducement
seekingalpha  ·  05-20 20:12
Inhibikase Therapeutics prices its direct offering, warrant inducement
Dyne Therapeutics Discloses Positive Trial Data for DYNE-101, DYNE-251 Treatments
Dow Jones  ·  05-20 19:12
Dyne Therapeutics Discloses Positive Trial Data for DYNE-101, DYNE-251 Treatments
Buy Rating Affirmed: Autolus Therapeutics’ Strategic Position and Upcoming Catalysts Promise Upside Potential
TIPRANKS  ·  05-20 18:17
Buy Rating Affirmed: Autolus Therapeutics’ Strategic Position and Upcoming Catalysts Promise Upside Potential
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
PR Newswire  ·  05-20 18:00
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
Buy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350
TIPRANKS  ·  05-20 17:55
Buy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350
Virios Therapeutics shares slid on pricing public offering of units to raise $1.7M
seekingalpha  ·  05-20 15:48
Virios Therapeutics shares slid on pricing public offering of units to raise $1.7M

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Issue price:
--